Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

FLJ44606 Inhibitors

FLJ44606 inhibitors represent a class of chemical compounds that specifically target the FLJ44606 protein or its associated signaling pathways. FLJ44606, also known as DDX6, is an RNA helicase that plays a critical role in RNA metabolism, including processes like RNA decay, translational repression, and the formation of cytoplasmic processing bodies (P-bodies). These inhibitors function by interacting with the protein's key domains, such as the helicase or ATP-binding domains, disrupting its ability to unwind RNA or mediate RNA-protein interactions. This disruption affects various cellular functions, especially those associated with post-transcriptional gene regulation and RNA stability, leading to alterations in protein synthesis and gene expression patterns.

The mechanisms of FLJ44606 inhibitors are often highly specific, binding to essential active sites within the protein or preventing its interaction with other cellular machinery involved in RNA processing. The inhibition of FLJ44606 can lead to profound effects on cellular pathways dependent on efficient RNA turnover and translational regulation, affecting key processes such as cell growth, differentiation, and stress responses. Additionally, these inhibitors may interfere with the formation or function of P-bodies, which are crucial for RNA storage and degradation. As a result, FLJ44606 inhibitors are valuable tools in molecular biology for studying the role of DDX6 and related RNA helicases in cellular homeostasis and gene regulation.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

A potent kinase inhibitor that interferes with the phosphorylation of multiple proteins, which may affect FLJ44606 if it is phosphorylation-dependent for its activity.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

A phosphoinositide 3-kinase inhibitor that can alter downstream signaling pathways, potentially affecting the activity of FLJ44606 if it is involved in PI3K signaling.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

An inhibitor of MEK, which could disrupt the MAPK/ERK pathway, possibly affecting FLJ44606 if it is a downstream effector in this pathway.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

An mTOR inhibitor that can lead to reduced protein synthesis and may inhibit FLJ44606 if its function is mTOR pathway-dependent.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

A p38 MAPK inhibitor that may impact FLJ44606 if it plays a role in the p38 MAPK stress response pathways.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

A selective inhibitor of MEK1/2, which can inhibit the ERK pathway and may affect FLJ44606 if it is regulated by the ERK signaling cascade.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

A potent inhibitor of phosphoinositide 3-kinases which could alter signaling pathways that regulate FLJ44606 if it is part of the PI3K pathway.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

An inhibitor of JNK, potentially affecting FLJ44606 if it is involved in the JNK signaling pathway.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$182.00
$693.00
88
(1)

A ROCK inhibitor that might impact the actin cytoskeleton and cell motility pathways, possibly influencing FLJ44606 if it is associated with these processes.

Bisindolylmaleimide I (GF 109203X)

133052-90-1sc-24003A
sc-24003
1 mg
5 mg
$103.00
$237.00
36
(1)

A broad-spectrum protein kinase C inhibitor that could affect FLJ44606 if PKC signaling modulates its function.